The threat of infectious disease is always present as the emergence of new epidemics reminds us. However, we are fortunate that unprecedented scientific and technological breakthroughs are making it possible to provide new medical solutions. The science and the public health challenges are both extremely complex, requiring a global approach to health care: an interdisciplinary, network-based approach, without borders of any kind, that is patient-centered and guarantees the same level of care to all patients regardless of their country of origin. This is Institut Mérieux’s vision of health care, which inspires all of our activities and our commitment to pushing the boundaries of biology.
Alain Mérieux, Chairman – Institut Mériux
Institut Mérieux is an independent, family-owned French group established in 1897 following in the footsteps of Louis Pasteur, serving medicine and Public Health across the globe.
To fight against infectious diseases and cancers, Institut Mérieux creates, innovates and develops new approaches in the fields of diagnostics, immunotherapy, food safety and nutrition.
Its three bio-industrial companies: bioMérieux, Transgene and Mérieux NutriSciences, work closely with its entities devoted to innovation: ABL Inc. and Mérieux Equity Partners, to enable major global advances in medicine and public health.
Bolstered by their expertise in biology, Institut Mérieux’s companies are focused on improving global public health through a comprehensive approach that combines disease and risk prevention with better patient care, from disease diagnosis to therapeutic treatment.
